Scarica l'app Stockscreener
2.21
0.00%
0.00
Dopo l'orario di chiusura:
2.20
-0.010
-0.45%
Precedente Chiudi:
$2.21
Aprire:
$2.271
Volume 24 ore:
8,649
Relative Volume:
0.25
Capitalizzazione di mercato:
$33.38M
Reddito:
-
Utile/perdita netta:
$-16.26M
Rapporto P/E:
-1.8707
EPS:
-1.1814
Flusso di cassa netto:
$-13.50M
1 W Prestazione:
-9.01%
1M Prestazione:
+25.57%
6M Prestazione:
-54.34%
1 anno Prestazione:
-55.08%
Intervallo 1D:
$2.1808
$2.33
Intervallo di 1 settimana:
$2.01
$2.56
Portata 52W:
$1.50
$5.94
Intensity Therapeutics Inc Stock (INTS) Company Profile
Nome
Intensity Therapeutics Inc
Settore
Industria
Telefono
203-221-7381
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Confronta INTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
2.21 | 33.38M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Clinical Trials News Live Feed - StockTitan
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Major Breakthrough: Advanced Cancer Trial Clears Critical Safety Milestone for Revolutionary Treatment - StockTitan
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV
Intensity Therapeutics' Cancer Drug Shows Dramatic 3X Survival Benefit in Phase 1/2 Sarcoma Trial - StockTitan
Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus
Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia
Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com
Internal Radiation Therapy - Market.us
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Myelodysplastic Syndrome (MDS) Drugs Market Trends and Sales Forecast to 2030: Total Revenues to Reach US$4.1 Billion Worldwide, with Immunomodulatory Drugs Dominating Shares - GlobeNewswire
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Top pharma biotech companies R&D intensity globally 2023 - Statista
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
Candel Therapeutics Prostate Cancer Therapy Shows Promise - Yahoo Finance
Candel Therapeutics stock up 172% after Phase III prostate cancer success - Yahoo Finance
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - The Eastern Progress Online
Intensity Therapeutics stock hits 52-week low at $2.46 By Investing.com - Investing.com Canada
Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):